Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Investor Presentation (November 2026)
24 slides from Hansa Biopharma Ab's investor presentation, November 2026
Slide 1: Corporate Presentation November 2026
® Corporate Presentation November 2026
Slide 2: Forward-looking statements
Forward-looking statements ® DISCLAIMER This presentation is made pursuant to Section 5(d) and/or Rule 163(b) of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or accredited investors solely for the purposes of familiarizing such
Slide 3: Novel, first-in-class IgG-cleaving enzyme from proprietary technology platform
Novel, first-in-class IgG-cleaving enzyme from proprietary technology platform ® Hansa’s IgG-cleaving Platform Provides unmatched speed in reducing IgG Imlifidase – proprietary, first in class IgG cleaving enzyme Rapid and targeted reduction of all IgG to > 95% in 2- 6 hours Cleaves all classes
Slide 4: Addressing orphan and rare autoimmune indications
Addressing orphan and rare autoimmune indications ® Therapeutic Focus Regulatory Status Desensitization Idefirix conditionally approved in Europe and UK Enabling Transplantation For desensitization prior to kidney transplantation with deceased donor Paradigm shift for highly sensitized kidney tran
Slide 5: Desensitization: Transplantation
® DESENSITIZATION Transplantation © 2026, Hansa Biopharma AB
Slide 6: US Kidney Transplant: A Growing Market with High Unmet Needs
US Kidney Transplant: A Growing Market with High Unmet Needs ® Significant unmet medical need with thousands of highly sensitized patients waiting for a transplant US Kidney Transplant Waitlist is Growing ~27,000 ~560,000 on dialysis in the US transplanted/year with 80% being deceased donor organs ~
Slide 7: Robust U.S. commercialization strategy established
Robust U.S. commercialization strategy established ® Concentrated Market Pricing and Reimbursement Experienced US Team ~200 kidney transplant centers 2/3 of patients have Medicare Medical Affairs Focused field-based team with strong transplant market experience Medicare covers kidney transplant vi
Slide 8: Successful US ConfIdeS Phase 3 study
Successful US ConfIdeS Phase 3 study ® Highly statistically significant outcome (p<0.0001) Imlifidase Control Imlifidase Control p-value n n eGFR (mean) eGFR (mean) Primary endpoint 32 32 51.5 19.3 <0.0001 eGFR at 12 months in FAS Rank-based non-parametric analysis of eGFR at 32 32 50.0* 0* 0.0001 1
Slide 9: Summary of ConfIdeS study outcomes
Summary of ConfIdeS study outcomes ® Highly statistically significant outcome (p<0.0001) At 1-year post-randomization, desensitization with imlifidase was associated with clinically meaningful and statistically significant kidney function measured as eGFR 51.5 mL/min/1.73 m2 which was superior t
Slide 10: Long-term follow-up study showed durable graft and patient survival
Long-term follow-up study showed durable graft and patient survival ® Study Overview Extended pooled analysis from the 17-HMedIdeS-14 study A long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase Key Takeaways (outcomes similar to n
Slide 11: Positive Data from Post Approval Confirmatory Study (PAES)
Positive Data from Post Approval Confirmatory Study (PAES) ® PAES Topline Results Out-licensing Transaction 50 highly sensitized patients transplanted across 22 €110 million Transaction closed July 1st, 2026. sites Exclusive out-licensing of Idefirix for transplantation in Primary objective
Slide 12: Desensitization: Gene Therapy
® DESENSITIZATION Gene Therapy © 2026, Hansa Biopharma AB
Slide 13: Collaborating to bridge access to gene therapies for more patients
Collaborating to bridge access to gene therapies for more patients ® Current Partnerships Indication exclusivity Indication exclusivity Duchenne Muscular Dystrophy Crigler-Najjar syndrome – (DMD) - 1/3,500 to 5,000 male ultrarare condition with births worldwide approximate incidence is 0.6-1 cas
Slide 14: Novel Compound – Autoimmune Focus: HNSA-5487
® Novel Compound – Autoimmune Focus HNSA-5487 © 2026, Hansa Biopharma AB
Slide 15: Rare autoimmune disease - IgG mediated conditions
Rare autoimmune disease - IgG mediated conditions ® Guillain-Barré Syndrome Guillain-Barré Syndrome Incidence A rare, acute, paralyzing, inflammatory disease of the peripheral nervous system caused by the immune system damaging nerve cells and structures. Rapid onset and progression of muscle we
Slide 16: Phase 2 Study demonstrated the role imlifidase may play in halting progression of GBS
Phase 2 Study demonstrated the role imlifidase may play in halting the progression of GBS ® Phase 2 Study Results Rapid overall improvement in functional status including expedited muscle recovery 37% of patients able to walk independently at Week 1 67% of patients able to walk independently a
Slide 17: Phase 1 clinical data with HNSA-5487
Non-human host derived; Phase 1 clinical data with HNSA-5487 ® Data demonstrated significantly lower immunogenicity for HNSA-5487 with rapid and robust IgG reduction Study Overview Double blind, randomized, placebo-controlled trial in 36 healthy volunteers received single ascending doses of HNSA-5
Slide 18: Financials and Outlook
® FINANCIALS AND OUTLOOK © 2026, Hansa Biopharma AB
Slide 19: Company profile & financial highlights
Company profile & financial highlights ® Positive PAES data Successful US ConfIdeS IND submission to FDA and PDUFA date December 19, 2026 initiation of Clinical supporting filing for full Phase 3 study with approval of Idefirix in Europe Followed by US commercial Development Program in statistically
Slide 20: Validated, high value pipeline with transformative milestones ahead
Validated, high value pipeline with transformative milestones ahead ® ATC US Potential US GBS clinical ConfIdeS full data approval of development plan presentation imlifidase established Potential US commercial launch Closing of SERB Filing for full Topline data Out-licensing approval for Idefirix E
Slide 21: Focused Pipeline in Desensitization and Autoimmune Diseases
® Focused Pipeline in Desensitization and Autoimmune Diseases Preclinical Phase 1 Phase 2 Phase 3 Marketed Partner Upcoming Milestone Desensitization Kidney Transplantation Filing with EMA for full approval in Q4 Out-licensing agreement effective July 1, 2026* Desensitization Kidney Transplantation
Slide 22: Experienced and Proven Leadership Team
Experienced and Proven Leadership Team Proven track record delivering growth, approvals, and launches across renal, rare disease, and immunology ® Renée Aguiar-Lucander Maria Törnsén Chief Executive Officer Chief Operating Officer, President US 20+ yrs rare disease leader and former investor, Succes
Slide 23: Other opportunities
Other opportunities ® Transplantation, other solid organs Kidney transplantation, living donor Desensitization to enable gene therapy IgG generated Autoimmune diseases as GBS Potential in licensing and/or acquisitions Kidney Potential out licensing to transplantation, other geographical regions dece
Slide 24: Hansa Biopharma
IZ HAN SAP BIOPHARMA
Hansa Biopharma — Investor Presentation (November 2026) on 6ix